Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

Regeneron (NASDAQ:REGN) announced Tuesday that Eylea HD, the high-dose version of its blockbuster eye care medication Eylea ...

Regeneron is racing to carve out a new market for the high-dose version of its blockbuster eye drug. In a recent study, the ...

Cytokinetics also stands to receive up to 490 million euros from Bayer, depending on certain sales milestones. The deal covers certain uses of drug candidate aficamten in hypertrophic ...

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA ...

Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial ...

Bayer is breaking into the irritable bowel syndrome (IBS) therapy market with the acquisition of HiDoc Technologies, which ...